SUBSCRIBE
SUBSCRIBE

BridgeBio LLC

NEWS
Biotech Bay
BridgeBio Launches QED Therapeutics With $65M and an Abandoned Novartis Cancer Program
BridgeBio stepped in to take over the drug and also launch a subsidiary, QED Therapeutics, to drive the development of infigratinib.
January 30, 2018
 · 
2 min read
 · 
Alex Keown
Biotech Bay
BioPharm Executive: Money Talk
Venture capital is hopping, attracted to some of the past several years’ successes.
October 14, 2017
 · 
1 min read
 · 
Karl Thiel
3 Biotechs That Could be Taken Out This Quarter
Business
Bay Area Startup BridgeBio Quietly Snags $135 Million From a Bunch of Wall Street Firms
September 13, 2017
 · 
2 min read
3 Biotechs That Could be Taken Out This Quarter
Business
Another Biotech is Born as Bay Area’s BridgeBio Pharma Launches Eidos Therapeutics With $27 Million
April 27, 2017
 · 
2 min read
Load More
AWARDS
  • 2026 - Best Places to Work - Badge (1).png
  • 2022 Best Places to Work
JOBS
IN THE PRESS
Biotech Bay
BridgeBio launches BridgeBio Oncology Therapeutics (BBOT) with $200M of private external capital to accelerate the development of its novel precision oncology pipeline
May 2, 2024
 · 
7 min read
Drug Development
BridgeBio Pharma Presents Cardiac Magnetic Resonance (CMR) Imaging Evidence Consistent with Clinical Improvement Observed in the ATTRibute-CM Phase 3 Study in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
April 7, 2024
 · 
8 min read
Biotech Bay
BridgeBio Pharma Announces Pricing of Public Offering of Common Stock - March 06, 2024
March 5, 2024
 · 
4 min read
Biotech Bay
BridgeBio Pharma Announces Proposed Public Offering of Common Stock - March 04, 2024
March 4, 2024
 · 
4 min read
Biotech Bay
BridgeBio Pharma and Bayer Announce European Licensing Agreement for Acoramidis in ATTR-CM
March 4, 2024
 · 
7 min read
Biotech Bay
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - February 06, 2024
February 6, 2024
 · 
1 min read
Deals
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - January 10, 2024
January 10, 2024
 · 
1 min read
Biotech Bay
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - December 08, 2023
December 8, 2023
 · 
1 min read
Biotech Bay
BridgeBio Pharma Announces Submission of New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Acoramidis for the Treatment of Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
December 5, 2023
 · 
7 min read
Drug Development
BridgeBio Pharma Presents Additional Clinical Outcomes Data from the Phase 3 ATTRibute-CM Study of Acoramidis in Patients with Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)
November 12, 2023
 · 
8 min read
Load More